Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05674227 | Cost-effectiveness Evaluation of Robotic Surgery in the Removal of Lung Lesions in the ATS of Milan | unknown | — | 5,400 | Agenzia di Tutela della Salute della Città Metropolitana di MilanoOTHER_GOV | 0 | Feb 1, 2023 | clinicaltrials |
| NCT05707585 | Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage | unknown | — | 2,064 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER |
| 1 |
| Feb 1, 2023 |
| clinicaltrials |
| NCT05068973 | Evaluation of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Lung Cancer Patients(LUCIOLA) | unknown | N/A | 35 | Hospital St. Joseph, Marseille, FranceOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05701384 | Lazertinib 160mg in EGFR T790M NSCLC | unknown | Phase 2 | 117 | Samsung Medical CenterOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02301858 | Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases | unknown | N/A | 100 | Janna BergOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02428049 | Radiation Pneumonitis After SBRT for NSCLC | unknown | — | 105 | Sykehuset i Vestfold HFOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05689437 | MIRA Clinical Learning Environment (MIRACLE): Lung(MIRACLE) | unknown | — | 1,000 | University Health Network, TorontoOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(FOCUS-A) | unknown | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05668767 | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | unknown | Phase 2 | 20 | Beijing Chest HospitalOTHER | 0 | Dec 30, 2022 | clinicaltrials |
| NCT04049942 | Comparing the Impact of Multimodal Prehabilitation to Aerobic Training on Patients Undergoing Thoracoscopic Lobectomy | unknown | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05662813 | Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy | unknown | Phase 2 | 55 | West China HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05655663 | Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer(IMMUNOVASC) | unknown | N/A | 30 | Centre Henri BecquerelOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT04436406 | PD-L1 Expression in Cancer (PECan Study).(PECan) | unknown | N/A | 30 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | unknown | Phase 2 | 28 | Tiziana Life Sciences LTDINDUSTRY | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05652712 | A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study) | unknown | — | 200 | Qianfoshan HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05648370 | Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery | unknown | — | 60 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05641870 | Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC | unknown | — | 80 | Parc de Salut MarOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT02331290 | Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen | unknown | — | 20 | University of ManitobaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04758481 | Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer | unknown | N/A | 20 | University Hospital OstravaOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03574402 | Phase II Umbrella Study Directed by Next Generation Sequencing(TRUMP) | unknown | Phase 2 | 400 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2022 | clinicaltrials |
| NCT05078918 | Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors | unknown | N/A | 800 | Samsung Medical CenterOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05611450 | Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy | unknown | N/A | 108 | Chang Gung Memorial HospitalOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05187767 | Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs | unknown | — | 80 | University of Roma La SapienzaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT04654104 | Immune Checkpoints in COPD(CP-COPD) | unknown | — | 80 | University of CatanzaroOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603013 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | unknown | Phase 2 | 45 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04923412 | Vagus Nerve Preservation and Chronic Cough in Non-small Cell Lung Cancer Surgery | unknown | N/A | 214 | Seoul National University Bundang HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05587114 | Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood | unknown | — | 150 | Korea University Guro HospitalOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05583916 | Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery(VALUE) | unknown | N/A | 20 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03317080 | Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer(LUNGCA) | unknown | — | 400 | West China HospitalOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05583409 | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC | unknown | N/A | 72 | Li ZhangOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05577052 | SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases | unknown | N/A | 100 | Wuhan UniversityOTHER | 0 | Oct 13, 2022 | clinicaltrials |
| NCT05574998 | First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial(FTANLCNDG) | unknown | Phase 2 | 100 | Qianfoshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05565677 | Prognostic Value of Lung Cancer MicroAnatomy in 3D(LungCaMa3D) | unknown | — | 50 | Aristotle University Of ThessalonikiOTHER | 0 | Oct 4, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Feb 1, 2023source: clinicaltrials